Supplementary Table 3.Summary of the most common (reported in ≥3% of patients) procedure- and/or device-related non-serious AEs and all SAEs in the study eye over 2 years of follow-up (ITT population).

|  | ITT population  (*N* = 67) |
| --- | --- |
| Non-serious AE, *n* (%) |  |
| Investigator-reported increased IOPa | 20 (29.9) |
| Hyphema | 17 (25.4) |
| Transient hypotony (IOP <6 mmHg at any time)b | 12 (17.9) |
| Keratitisc | 8 (11.9) |
| Corneal ulcer | 4 (6.0) |
| Drug allergy | 4 (6.0) |
| Tube touching iris | 3 (4.5) |
| Conjunctival hemorrhage | 2 (3.0) |
| Macular edema | 2 (3.0) |
| Ocular irritation | 2 (3.0) |
| Retinal complicationd | 2 (3.0) |
| Suture bleed/suture complication | 2 (3.0) |
| SAE, *n* (%) |  |
| Bleb leak | 1 (1.5) |
| Implant migration | 1 (1.5) |
| Investigator-reported increased IOPe | 1 (1.5) |

aFollowing the event of non-serious increased IOP, 7 patients required postoperative needling, 6 patients received medication, 5 patients received medication/needling, 3 patients required no intervention, 1 patient required postsurgical MMC injection of bleb area, and 1 patient underwent surgical procedure/needling. bCases of hypotony resolved after 15.8 ± 11.2 days. cDefined as small defects in the corneal epithelium. dDialysis, flap tears, detachment, decompression, or proliferative retinopathy. eFollowing the event of serious increased IOP, 1 patient underwent surgical procedure. AE, adverse event; IOP, intraocular pressure; ITT, intention-to-treat; MMC, Mitomycin C; SAE, serious adverse event.